Reference
(1) Anon. Pdf.hres.ca. (2019). [online] Available at:
https://pdf.hres.ca/dpd_pm/00039841.PDF [Accessed 20 Oct. 2019].
(2) Perazella MA. Trimethoprim-induced hyperkalaemia. Drug Safety.
2000;1;22(3):227-36.
(3) Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani
MM, et al. Co-trimoxazole and sudden death in patients receiving
inhibitors of renin-angiotensin system: population based study. British
Medical Journal 2014;30;349:g6196.
(4) Deray G, Benhmida M, Le Hoang P, Maksud P, Aupetit B, Baumelou A, et
al. Renal function and blood pressure in patients receiving long-term,
low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Annals
of Internal Medicine. 1992;1;117(7):578-83..
(5) Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM.
Trimethoprim-sulfamethoxazole–induced hyperkalemia in patients
receiving inhibitors of the renin-angiotensin system: a population-based
study. Archives of Internal Medicine. 2010;28;170(12):1045-9..
(6) Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, et al.
Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of
hyperkalemia requiring hospitalization in the elderly: a nested
case-control study. Clinical Journal of the American Society of
Nephrology. 2010; 1;5(9):1544-51.
(7) Sahu M, Singh S, Das A, Abraham A, Airan B, Alam I, et al. High
blood tacrolimus and hyperkalemia in a heart transplant patient. Annals
of Cardiac Anaesthesia. 2017; 1;20(2).
(8) Mori H, Kuroda Y, Imamura S, Toyoda A, Yoshida I, Kawakami M, et al.
Hyponatremia and/or hyperkalemia in patients treated with the standard
dose of trimethoprim-sulfamethoxazole. Internal Medicine.
2003;42(8):665-9.
(9) Yang ZW. ASHP guidelines on adverse drug reaction monitoring and
reporting. Pharmaceutical Care and Research. 2002;2(3):189-91.